Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
Becton, Dickinson and Company has recast its historical financial statements to reflect the February 9, 2026 spin-off and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation. The recast data present BD as a standalone company, treating that business as discontinued operations.
For the twelve months ended September 30, 2025, BD reported revenues of $18,544 million and net income from continuing operations of $1,100 million, with diluted earnings per share from continuing operations of $3.81, compared with $16,820 million, $1,054 million and $3.62 in 2024. BD also provides non-GAAP measures that adjust for purchase accounting, integration and restructuring costs, separation-related items, certain regulatory and legal costs, and related tax effects to highlight underlying operating performance.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, sold 75 shares of common stock at $156.83 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. After this planned sale, he directly owns 21,233 shares.
Michael Feld reports proposed and completed sales of Common Stock. The filing lists a proposed sale of 75 Restricted Stock Units to be sold through the issuer on 08/20/2025. It also records two 10b5-1 sales by Michael Feld of 75 shares each on 02/26/2026 and 01/26/2026 with amounts shown as 13638.00 and 15204.75, respectively.
The broker listed is Morgan Stanley Smith Barney LLC at New York Plaza. The filing is a routine notice of sale under Form 144 and documents the seller, security type, sale dates, and per-sale amounts as provided.
Becton Dickinson & Co Schedule 13G/A (Amendment No. 14) reports that The Vanguard Group disaggregated certain subsidiaries following an internal realignment and now reports 0 shares beneficially owned of the company's common stock, representing 0% of the class. The amendment explains the change is in accordance with SEC Release No. 34-39538 and reflects separate reporting by subsidiaries effective after the internal reorganization.
Becton Dickinson & Co executive Lanesha Minnix received an equity award of 7,492 shares of Common Stock on March 16, 2026. The Form 4 classifies this as a grant or award acquisition at no purchase price. A footnote explains the award represents restricted stock units granted under the company’s 2004 equity-based compensation plan. Following this grant, Minnix directly holds 7,492 shares.
Becton Dickinson & Co executive Lanesha Minnix, EVP and General Counsel, filed an initial Form 3 reporting her beneficial ownership in the company. The filing shows she held no shares of Becton Dickinson common stock directly as of the reporting date and reports no transactions.
Becton Dickinson & Co. interim CFO Vitor Roque reported receiving a grant of 931 shares of common stock on March 2, 2026, at a stated price of $0.00 per share as a stock award. After this acquisition, his directly held stake increased to 6,510 common shares. A footnote explains that his direct holdings reflect adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
BECTON DICKINSON & CO senior vice president, controller and chief accounting officer Pamela L. Spikner reported an acquisition of 931 shares of common stock as a grant or award at a price of $0.00 per share. Following this transaction, her directly held stake is 3,323 common shares.
A footnote explains that her direct holdings reflect adjustments tied to the combination of the company’s Biosciences and Diagnostic Solutions businesses with Waters Corp., affecting the number of shares underlying previously reported, unvested time-vested restricted stock units.
Becton Dickinson & Co EVP and Chief Revenue Officer Michael Feld sold 75 shares of common stock in an open-market transaction at $181.84 per share. After this sale, he directly holds 21,308 shares. A footnote notes prior adjustments to his direct holdings tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
BDX submission under Rule 144 reports a proposed sale of 75 restricted stock units tied to an 08/20/2025 grant. The filing also lists recent 10b5-1 sales by Michael Feld on 01/26/2026 (75), 12/26/2025 (74) and 12/01/2025 (75), with the amounts shown alongside each trade.